DEVELOPMENT, LICENSING AND
This Development, Licensing and Manufacturing Agreement ("Agreement") is made as of the 10th day of May,
2001, by INMEDICA DEVELOPMENT CORPORATION, a Utah corporation ("InMedica"), and CHI LIN
TECHNOLOGY CO., LTD., a corporation duly organized and existing under the laws of the Republic of China
The parties are executing this Agreement is connection with their execution of a Stock Purchase Agreement dated
the 10th day of May 2001 (the "Stock Purchase Agreement"), by which Chi Lin is purchasing from InMedica
and InMedica is issuing to Chi Lin stock in InMedica and MicroCor. The execution of this Agreement is a
condition precedent to the parties' obligations under the Stock Purchase Agreement.
InMedica is a medical products research and development company. It has developed a method for measuring
hematocrit non-invasively (without drawing blood) and has applied for and/or received three (3) patents from the
U.S. Patent and Trademark Office. As of February 15, 1995, InMedica's application for a patent entitled
"Method and Apparatus for Non-invasively Determining Hematocrit " was allowed by the U.S. Patent and
Trademark Office, and such patent issued on June 18, 1996, as Patent No. 5526808 with term of 17 years.
InMedica filed an application for an additional patent, which claims priority from October 4, 1990, the date of the
first patent's filing. The second patent was issued on July 1 1997 as patent No. 5,642,734, Method and
Apparatus for Noninvasively Determining Hematocrit As of December 21, 1999, InMedica received a first office
action notice of allowance on a third patent, "System and Method for Invivo Hematocrit Measurement Using
Impedance and Pressure Plethysmography." On October 3, 2000 this patent was issued as patent No.
6,128,518. On May 16, 2000 InMedica filled for a fourth patent System and Method for In-Vivo Hematocrit
Measurement Using Impedance and Pressure Plethysmography. This patent application is c